Alvotech In-Licenses Xolair Rival From BiosanaPharma
Co-Development Deal Will See Pair Collaborate On Omalizumab Biosimilar
Alvotech has delivered on indications that it would look to collaborate on certain biosimilar opportunities in future, striking a licensing deal with BiosanaPharma that will see the two firms partner to co-develop an omalizumab biosimilar rival to Xolair.
You may also be interested in...
Alvotech has begun its fourth biosimilar clinical trial program, announcing the start of studies for its AVT03 proposed denosumab rival to Prolia/Xgeva.
Alvotech will cease to be a privately listed company next week, with its merger with special purpose acquisition company Oaktree Acquisition Corp. II set to close “on or about 15 June.”
Alvotech and AbbVie have settled all of their legal disputes over Alvotech’s AVT02 biosimilar rival to Humira. With Alvotech seeking a coveted interchangeability designation for its higher-strength adalimumab, the firm’s US entry date provided by the settlement matches that of Boehringer Ingelheim’s interchangeable Cyltezo lower-strength adalimumab biosimilar.